Published in Support Care Cancer on July 01, 1997
Development and preliminary validation of a risk prediction model for chemotherapy-related nausea and vomiting. Support Care Cancer (2013) 2.26
Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer (2006) 1.54
The impact of chemotherapy-induced nausea and vomiting on health-related quality of life. Support Care Cancer (2006) 1.41
Impact of nausea and vomiting on quality of life in cancer patients during chemotherapy. Health Qual Life Outcomes (2003) 1.34
Chemotherapy-induced nausea and vomiting in routine practice: a European perspective. Support Care Cancer (2004) 1.30
Insight in the prediction of chemotherapy-induced nausea. Support Care Cancer (2009) 1.28
A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre. Support Care Cancer (2007) 1.27
A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Support Care Cancer (2005) 1.18
The impact of chemotherapy-related nausea on patients' nutritional status, psychological distress and quality of life. Support Care Cancer (2012) 1.08
Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy. Support Care Cancer (2010) 1.06
Palonosetron (Aloxi) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy. Support Care Cancer (2008) 1.05
One third of patients with radiotherapy-induced nausea consider their antiemetic treatment insufficient. Support Care Cancer (2008) 1.00
A review of patient self-report tools for chemotherapy-induced nausea and vomiting. Support Care Cancer (2008) 0.97
Aprepitant and fosaprepitant: a 10-year review of efficacy and safety. Oncologist (2015) 0.97
A systematic review and meta-analysis of intravenous palonosetron in the prevention of chemotherapy-induced nausea and vomiting in adults. Oncologist (2011) 0.91
A randomized controlled trial of mindfulness-based stress reduction for women with early-stage breast cancer receiving radiotherapy. Integr Cancer Ther (2013) 0.91
Utilization of hypnotic medication in the context of cancer: predictors and frequency of use. Support Care Cancer (2011) 0.91
How do patient expectancies, quality of life, and postchemotherapy nausea interrelate? Cancer (2008) 0.89
Reduction of chemotherapy-induced anorexia, nausea, and emesis through a structured nursing intervention: a cluster-randomized multicenter trial. Support Care Cancer (2009) 0.88
Nausea still the poor relation in antiemetic therapy? The impact on cancer patients' quality of life and psychological adjustment of nausea, vomiting and appetite loss, individually and concurrently as part of a symptom cluster. Support Care Cancer (2012) 0.86
Comparative efficacy of serotonin (5-HT3) receptor antagonists in patients undergoing surgery: a systematic review and network meta-analysis. BMC Med (2015) 0.84
Integrating acupuncture into cancer care. J Tradit Complement Med (2013) 0.83
Nanomedicines in the treatment of emesis during chemotherapy: focus on aprepitant. Int J Nanomedicine (2007) 0.82
Safety of serotonin (5-HT3) receptor antagonists in patients undergoing surgery and chemotherapy: protocol for a systematic review and network meta-analysis. Syst Rev (2013) 0.82
A meta-analysis of olanzapine for the prevention of chemotherapy-induced nausea and vomiting. Sci Rep (2014) 0.82
Randomized, placebo-controlled trial of K1 acupoint acustimulation to prevent cisplatin-induced or oxaliplatin-induced nausea. Cancer (2014) 0.81
Randomized double-blind study of the Reliefband as an adjunct to standard antiemetics in patients receiving moderately-high to highly emetogenic chemotherapy. Support Care Cancer (2003) 0.79
Efficacy and safety of aprepitant in the prevention of chemotherapy-induced nausea and vomiting: a pooled analysis. Support Care Cancer (2011) 0.79
Palliative venting percutaneous endoscopic gastrostomy tube is safe and effective in patients with malignant obstruction. Surg Endosc (2013) 0.78
Antiemetic activity of megestrol acetate in patients receiving chemotherapy. Support Care Cancer (2010) 0.77
Phase II clinical trial of palonosetron combined with tropisetron in preventing chemotherapy-induced nausea and vomiting. Int J Clin Exp Med (2015) 0.76
Prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitant. Ther Clin Risk Manag (2008) 0.75
Efficacy of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting: A meta-analysis. Br J Clin Pharmacol (2017) 0.75
Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol (1998) 9.89
Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol (2010) 5.96
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst (2000) 5.62
Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol (1998) 3.79
Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet (1994) 3.51
Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol (2002) 3.11
Are long-chain polyunsaturated fatty acids essential nutrients in infancy? Lancet (1995) 2.73
Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol (2000) 2.58
Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol (1993) 2.56
Quinolone-based antibacterial chemoprophylaxis in neutropenic patients: effect of augmented gram-positive activity on infectious morbidity. National Cancer Institute of Canada Clinical Trials Group. Ann Intern Med (1996) 2.15
Psychometric properties and responsiveness of the EORTC quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Qual Life Res (1994) 2.11
Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol (1998) 2.05
Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma. Ann Oncol (2006) 2.04
Patterns of failure following loco-regional radiotherapy in the treatment of limited stage small cell lung cancer. Int J Radiat Oncol Biol Phys (1994) 2.01
Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer. J Clin Oncol (1990) 1.88
Cellular DNA content as a marker of human multiple myeloma. Blood (1980) 1.83
Application of a new multinomial phase II stopping rule using response and early progression. J Clin Oncol (2001) 1.77
Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer (2004) 1.76
Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int J Gynecol Cancer (2003) 1.70
Compliance with consensus recommendations for the treatment of early stage breast carcinoma in elderly women. Cancer (1999) 1.68
Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol (1999) 1.63
A double-blind placebo-controlled randomized study of Chinese herbal medicine as complementary therapy for reduction of chemotherapy-induced toxicity. Ann Oncol (2007) 1.63
Cellular DNA content as a marker of neoplasia in man. Am J Med (1980) 1.62
Adult paratesticular sarcomas: a review of 21 cases. J Urol (1991) 1.59
Thermography. Its relation to pathologic characteristics, vascularity, proliferation rate, and survival of patients with invasive ductal carcinoma of the breast. Cancer (1996) 1.57
Quality-of-life assessment: patient compliance with questionnaire completion. J Natl Cancer Inst (1992) 1.55
Quality of life scores: an independent prognostic variable in a general population of cancer patients receiving chemotherapy. The National Cancer Institute of Canada Clinical Trials Group. Qual Life Res (1997) 1.54
Function and health status outcomes in a randomized trial comparing preoperative and postoperative radiotherapy in extremity soft tissue sarcoma. J Clin Oncol (2002) 1.50
Sex differences in bleeding time and blood loss in normal subjects following aspirin ingestion. Thromb Res (1981) 1.44
A randomized controlled trial of the effects of group psychological therapy on survival in women with metastatic breast cancer. Psychooncology (1999) 1.43
Guideline adaptation: an approach to enhance efficiency in guideline development and improve utilisation. BMJ Qual Saf (2011) 1.39
Control of cancer-related pain with MS Contin: a comparison between 12-hourly and 8-hourly administration. J Pain Symptom Manage (1995) 1.39
Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol (2004) 1.39
Revertants of v-fos-transformed fibroblasts have mutations in cellular genes essential for transformation by other oncogenes. Cell (1987) 1.35
Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (1996) 1.32
Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. J Clin Oncol (1996) 1.31
Communicating quality of life information to cancer patients: a study of six presentation formats. J Clin Oncol (2005) 1.31
Palliative effect of chemotherapy: objective tumor response is associated with symptom improvement in patients with metastatic breast cancer. J Clin Oncol (2000) 1.30
Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (1997) 1.29
Quality-adjusted time without symptoms or toxicity analysis of interferon maintenance in multiple myeloma. J Clin Oncol (1998) 1.27
Outcome and prognostic factors in soft tissue sarcoma in the adult. Int J Radiat Oncol Biol Phys (1993) 1.26
A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. Breast Cancer Res Treat (2008) 1.26
Reliability of the time trade-off technique of utility assessment in patients with retinal disease. Can J Ophthalmol (2001) 1.22
Assessing the reliability of two toxicity scales: implications for interpreting toxicity data. J Natl Cancer Inst (1993) 1.22
The role of palliative thoracic radiotherapy in non-small cell lung cancer. Can J Oncol (1996) 1.20
High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy. J Viral Hepat (2004) 1.17
The impact of 18F-FDG PET/CT on assessment of nasopharyngeal carcinoma at diagnosis. Br J Radiol (2008) 1.15
Ploidy and proliferative characteristics in monoclonal gammopathies. Blood (1982) 1.15
Influence of measurement error on assessment of response to anticancer chemotherapy: proposal for new criteria of tumor response. J Clin Oncol (1984) 1.14
Variations in the treatment of early-stage breast cancer in Quebec between 1988 and 1994. CMAJ (1999) 1.08
Intracavitary brachytherapy significantly enhances local control of early T-stage nasopharyngeal carcinoma: the existence of a dose-tumor-control relationship above conventional tumoricidal dose. Int J Radiat Oncol Biol Phys (2000) 1.08
Ploidy, proliferative activity and estrogen receptor content in human breast cancer. Cytometry (1982) 1.07
Use of multiple correspondence analysis and cluster analysis to study dietary behaviour: food consumption questionnaire in the SU.VI.MAX. cohort. Eur J Epidemiol (2001) 1.06
The prognostic significance of pretreatment serum lactate dehydrogenase in patients with small-cell lung cancer. J Clin Oncol (1991) 1.06
Ectopic corticotropin syndrome and small-cell carcinoma of the lung. Clinical features, outcome, and complications. Arch Intern Med (1993) 1.05
Influence of age on the treatment of limited-stage small-cell lung cancer. J Clin Oncol (1996) 1.05
Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (1998) 1.05
Dexamethasone for the prophylaxis of radiation-induced emesis: a National Cancer Institute of Canada Clinical Trials Group phase III study. J Clin Oncol (2000) 1.04
Characterization of hematologic malignancies by flow cytometry. Blood Cells (1980) 1.04
Impact of chemotherapy-associated nausea and vomiting on patients' functional status and on costs: survey of five Canadian centres. CMAJ (1993) 1.03
Prevalence of CYP1B1 mutations in Australian patients with primary congenital glaucoma. Clin Genet (2007) 1.03
Small-cell carcinoma of the lung: derivation of a prognostic staging system. J Clin Oncol (1991) 1.03
Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. J Clin Oncol (1999) 1.02
Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8. J Clin Oncol (2000) 1.02
Consensus proposal for 5HT3 antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy. Dose, schedule, and route of administration. Support Care Cancer (1998) 1.00
A multicenter comparative trial of tobramycin and ticarcillin vs moxalactam and ticarcillin in febrile neutropenic patients. Arch Intern Med (1985) 1.00
Cost-effectiveness of cancer chemotherapy: an economic evaluation of a randomized trial in small-cell lung cancer. J Clin Oncol (1988) 0.99
Trabecular microstructure in the medial condyle of the proximal tibia of patients with knee osteoarthritis. Bone (1995) 0.99